A clinical trial into puberty blockers for children has been paused after the medicines regulator warned it should have a minimum age limit of 14 because of the “unquantified risk” of “long-term biological harms”.
The Medicines and Healthcare products Regulatory Agency will now discuss the concerns, related to the wellbeing of children and young people, with trial sponsor King’s College London next week and recruitment to the trial will not start until the issues have been resolved.
